Coronavirus Outbreak: WHO pauses trial of hydroxychloroquine over safety concerns, clinical tests of other potential treatments to continue

The World Health Organization has suspended testing the malaria drug hydroxychloroquine in COVID-19 patients due to safety concerns

Reuters May 26, 2020 09:03:56 IST
Coronavirus Outbreak: WHO pauses trial of hydroxychloroquine over safety concerns, clinical tests of other potential treatments to continue

Geneva: The World Health Organization (WHO) has suspended testing the malaria drug hydroxychloroquine in COVID-19 patients due to safety concerns, WHO Director General Tedros Adhanom Ghebreyesus said on Monday.

Hydroxycholoroquine has been touted by Donald Trump and others as a possible treatment for the disease caused by the novel coronavirus. The US President has said he was taking the drug to help prevent infection.

“The executive group has implemented a temporary pause of the hydroxychloroquine arm within the Solidarity trial while the safety data is reviewed by the data safety monitoring board,” Tedros told an online briefing.

He said the other arms of the trial - a major international initiative to hold clinical tests of potential treatments for the virus - were continuing.

The WHO has previously recommended against using hydroxychloroquine to treat or prevent coronavirus infections, except as part of clinical trials.

Dr Mike Ryan, head of the WHO emergencies programme, said the decision to suspend trials of hydroxychloroquine had been taken out of “an abundance of caution”.

Updated Date:

also read

Coronavirus Outbreak: Member of Maharashtra govt's COVID-19 task force tests positive
India

Coronavirus Outbreak: Member of Maharashtra govt's COVID-19 task force tests positive

The task force of nine senior doctors was formed on 13 April in view of increasing number of coronavirus cases and deaths in the state, especially in Mumbai.

COVAXIN controversy: Bharat Biotech-ICMR readying a COVID-19 vaccine in 45 days baffles reason, ignores safety concerns, says bioethicist
India

COVAXIN controversy: Bharat Biotech-ICMR readying a COVID-19 vaccine in 45 days baffles reason, ignores safety concerns, says bioethicist

Dr Anant Bhan, a researcher in global health, bioethics and health policy and former president of International Association of Bioethics, spoke to Firstpost about the "extreme urgency" shown by ICMR in developing India's COVID-19 vaccine, COVAXIN, by 15 August

COVAXIN controversy: Doctors in trial sites chosen by ICMR say human trials can’t be fast forwarded, anticipate 6-month observation period
India

COVAXIN controversy: Doctors in trial sites chosen by ICMR say human trials can’t be fast forwarded, anticipate 6-month observation period

Hyderabad-based Bharat Biotech received approval from the Central Drugs Standard Control Organisation (CDSCO) to begin human trials of COVAXIN last week. The vaccine has been developed in collaboration with the ICMR and National Institute of Virology in Pune.